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Abstract: Cancer is frequently considered to be a disease of the cell cycle; alterations in different families of cell cycle 
regulators cooperate in tumor development. Molecular analysis of human tumors has shown that cell cycle regulators are 
frequently mutated in human neoplasms, which underscores how important the maintenance of cell cycle commitment is 
in the prevention of human cancer. The regulatory pathways controlling cell cycle phases include several oncogenes and 
tumor suppressor genes which display a range of abnormalities with potential usefulness as markers of evolution or treat-
ment response in epithelial ovarian cancer. This review summarizes the current knowledge about these aberrations in ma-
lignant tumors of the ovary. We sought to focus our attention on the genes involved in the development of tumors arising 
from the ovarian epithelium, which are the most common types of ovarian malignancies. 
Keywords: Cell cycle deregulation, ovarian malignancy, cancer therapy, ovarian carcinoma histotypes. 
INTRODUCTION 
  Ovarian cancer remains a highly lethal disease. In devel-
oped countries, ovarian cancer accounts for more deaths than 
all other gynecological malignancies combined; an estimated 
22,430 new cases and 15,280 deaths occurred in 2007 (Can-
cer Facts & Figures 2007). As the result of advances in sur-
gical management and chemotherapeutic options over the 
last three decades, the median survival times for ovarian 
cancer patients has improved. However, overall survival has 
not been significantly changed. In addition, most patients 
present with advanced disease for which highly effective 
curative therapy is currently unavailable. The epithelial tu-
mors of the ovary, which account for 90% of malignant 
ovarian tumors, are further divided into histological sub-
groups with different malignant potential endometrioid, 
mucinous, serous, clear cell and undifferentiated carcinomas. 
In follow-up studies, mucinous and endometrioid carcinomas 
have a less aggressive behavior and a better overall survival 
than serous tumors. A characteristic of serous, mucinous and 
endometrioid ovarian carcinomas is the low malignant po-
tential (LMP), or in the case of borderline tumors, a low risk 
of invasion.  
  The molecular pathology of ovarian carcinomas is het-
erogeneous and involves various putative precursor lesions 
and multiple pathways of development. The most common 
subtype, high-grade serous carcinoma, is characterized by 
p53 mutations, and BRCA1 and/or BRCA2 dysfunction. It 
most likely arises from epithelium within inclusion cysts or 
from the surface of the ovary. Dysregulation of cell cycle 
control, in particular G1-S-phase transition, is implicated in  
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the pathogenesis of most human cancers, including epithelial 
ovarian cancer (EOC). However, the prognostic significance 
of aberrant cell cycle gene expression in EOC remains 
mostly unclear. During the G1-S transition, the cy-
clinE/CDK2 and cyclinD/CDK4 complexes promote pro-
gression and are each inhibited by the associated CDK in-
hibitor p27
KIP1. If DNA damage occurs, p53 accumulates in 
the cells and induces the p21-mediated inhibition of cy-
clinD/CDK. The transition to S phase is triggered by the 
activation of the cyclinD/CDK complex, which phosphory-
lates the retinoblastoma protein pRb, a known cell prolifera-
tion regulator.  
  The members of the INK4 family, comprising p16 and 
p15, exert their inhibitory activity by binding to the CDK4 
and CDK6 kinases and preventing their association with D-
type cyclins. 
  In contrast to G1 regulators, less is known about the 
genes which regulate the S, G2 and M phases of the cell cy-
cle, such as cyclin A- and cyclin B-kinase complexes and 
their inhibitors. The significance of cell-cycle regulatory 
genes in carcinogenesis is underlined by the fact that most of 
them have been identified as proto-oncogenes or tumor sup-
pressor genes.  
  Expression of cell cycle markers has recently been linked 
to tumor behavior and response to treatment. Hopefully, a 
better understanding of the molecular mechanisms underly-
ing the tumorigenic process of ovarian carcinoma will lead 
to earlier diagnosis, novel therapies and ultimately better 
outcomes.  
SEROUS OVARIAN CARCINOMAS  
  Ovarian serous carcinoma is the most common and lethal 
type of ovarian cancer and its molecular etiology remains 
poorly understood. The expression of selected genes from 
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cluding cyclin D1, p16
INK4A, cyclin E, p27
KIP1, p21
WAF1/CIP1, 
and p53, was examined in a consecutive series of 134 serous 
epithelial ovarian cancers (EOC) using immunohistochemis-
try. Molecular markers predictive of reduced overall survival 
in univariate analysis were overexpression of cyclin D1 (P = 
0.03) and p53 (P = 0.03) and reduced expression of p27
KIP1 
(P= 0.05) and p21
WAF1/CIP1 (P = 0.02), with the latter three 
also being prognostic for a shorter progression-free interval. 
In addition, patients displaying overexpression of p53 with 
concurrent loss of p21
WAF1/CIP1 had a significantly shorter 
overall (P=0.0008) and progression-free survival (P=0.0001). 
On multivariate analysis, overexpression of cyclin D1 and 
combined loss of p21
WAF1/CIP1 in the presence of p53 overex-
pression were independent predictors of overall survival. 
Similarly, the combination of p21
WAF1/CIP1 loss and p53 over-
expression was independently predictive of a shorter pro-
gression-free interval. Overexpression of p53 and cyclin E 
and reduced expression of p27
KIP1 and p21
WAF1/CIP1 were sig-
nificantly associated with increasing tumor grade. This study 
confirms that dysregulation of cell cycle genes is common in 
EOC, and that aberrant expression of critical cell cycle regu-
latory proteins can predict patient outcome in serous EOC 
[1]. 
 Buchynska  et al. have shown that serous ovarian carci-
nomas are characterized by high proliferative activity (PI Ki-
67 = 30.0 +/- 0.3%), p53 and p16
INK4A overexpression and 
low expression of p21
WAF1/CIP1. The association between ex-
pression of these markers and ovarian tumor grade was de-
fined: the maximal level of Ki-67, p53 and p16
INK4A and 
minimal of p21
WAF1/CIP1 expression were observed in G3 tu-
mors. So, low p21
WAF1/CIP1 expression combined with 
p16
INK4A overexpression is considered to be a factor for a 
poor prognosis in serous ovarian cancer [2].  
  Reduced expression of the cyclin-dependent kinase in-
hibitor p27
KIP1 has been reported to be associated with poor 
prognosis in several human cancers. In serous ovarian can-
cers, positive p27
KIP1 staining rate was significantly higher in 
early stage than that in advanced stage diseases (p=0.030, 
Fisher's exact test). Log-rank testing showed that negative 
p27
KIP1 expression significantly correlates with poor survival 
in serous ovarian cancer patients (p=0.041). These results 
suggest that the underexpression of p27
KIP1 caused by post-
translational mechanism may contribute to the development 
and progression and result in poor prognosis of serous ovar-
ian cancers [3]. 
  It is well known that somatic mutation of p53 represents 
the most common molecular genetic alteration occurring in 
epithelial ovarian carcinoma. Inactivation of p53 was de-
tected in 30-80% of ovarian carcinoma [4, 5]. 
  Although p53 overexpression was a common feature of 
both mucinous and serous borderline tumors, p21
WAF1/CIP1 
overexpression appeared specific to serous tumors [6].  
  Statistical analyses showed a significantly higher expres-
sion of p53 in histologically high-grade tumors (grades 2 and 
3), mainly of the serous subtyp. A statistical tendency toward 
higher expression of p53 in older patients (P= 0.08) was also 
observed. p53 is associated with serous carcinoma, loss of 
differentiation, and older patients. These results are in keep-
ing with different pathogenetic pathways in subtypes of 
ovarian carcinoma, prompting the search for new strategies 
of prevention and treatment [7]. 
  The frequency of p53 mutation in early-stage ovarian 
carcinomas of serous histology is comparable to that re-
ported for advanced-stage tumors, and it is therefore likely to 
occur early in the progression of the most common his-
tological variant of ovarian carcinoma [8]. For invasive car-
cinomas, the rate of mutation and expression increases with 
increasing tumor grade and stage, and is more common in 
tumors of serous histology [9]. Palazzo et al. demonstrated 
that coexpression of p21
WAF1/CIP1 and MDM2 characterizes 
serous borderline tumors of the ovary and their implants, 
which suggests that these cell cycle control proteins are im-
portant in these tumors and may be related to tumor progres-
sion. Low expression of p53 protein in serous borderline 
tumors might be in part mediated by MDM2. This suggests 
that the p53 pathway is intact in most of these tumors, in 
contrast with carcinomas, in which high expression of p53 
has been related to mutations of this gene [10]. 
MUCINOUS CARCINOMAS 
  Mucinous carcinoma of the ovary accounts for 7% to 
14% of all primary EOC [11]. Distinction of primary ovarian 
epithelial tumors from metastatic adenocarcinomas is chal-
lenging for tumors exhibiting mucinous, endometrioid, or 
mixed endometrioid/mucinous differentiation. Metastatic 
carcinomas with these types of differentiation can be derived 
from several sites, including the gastrointestinal tract and the 
uterus. Most endocervical adenocarcinomas exhibit muci-
nous and/or endometrioid differentiation; they infrequently 
metastasize to the ovaries but may simulate primary ovarian 
tumors (both borderline and carcinoma). Most are high-risk 
human papillomavirus (HPV)-related and demonstrate dif-
fuse p16 over-expression due to complex molecular mecha-
nisms by which high-risk HPV transforming proteins interact 
with cell cycle regulatory proteins. Vang et al. evaluated this 
expression pattern for identifying metastatic endocervical 
adenocarcinomas in the ovaries among primary ovarian tu-
mors and other metastatic adenocarcinomas having muci-
nous and/or endometrioid/endometrioidlike differentiation. 
Immunohistochemical expression of p16 was assessed in 195 
tumors, including 102 primary ovarian tumors (51 mucinous, 
47 endometrioid, and 4 mixed mucinous-endometrioid tu-
mors), 82 metastatic adenocarcinomas of known primary 
sites (colorectum: 34, endocervix: 19, pancreaticobiliary 
tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarci-
nomas of unknown origin, and 4 adenocarcinomas of uncer-
tain origin. Mean and median p16 expression values for 
HPV-positive endocervical adenocarcinomas were substan-
tially higher than those for primary ovarian mucinous and 
endometrioid tumors, HPV-unrelated endocervical adenocar-
cinomas, metastatic adenocarcinomas of unknown origin, 
and adenocarcinomas of uncertain (primary ovarian vs. me-
tastatic) origin. Only the 15 HPV-positive endocervical ade-
nocarcinomas and 6 other tumors had values of 80% or 
greater. Diffuse (>75% positive tumor cells), moderate to 
strong p16 expression is a sensitive (100%) and specific 
(97%) marker for identifying HPV-related endocervical ade-
nocarcinomas metastatic to the ovary among the primary 
ovarian tumors and metastatic adenocarcinomas from other 
sites that are in the differential diagnosis of ovarian tumors 
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ferentiation. p16 is useful as part of a panel of immunohisto-
chemical markers for distinguishing primary ovarian tumors 
from metastases and, when diffusely positive, can suggest 
the cervix as a potential primary site for metastatic adenocar-
cinomas of unknown origin [12].  
  Patients with advanced mucinous EOC have a poorer 
response to platinum-based
  first-line chemotherapy com-
pared with patients with other histologic
 subtypes of EOC, 
and their survival is worse. Specific alternative
 therapeutic 
approaches should be sought for this group of patients,
 per-
haps involving fluorouracil-based chemotherapy [13]. 
ENDOMETRIOID CARCINOMAS 
 Plisiecka-Halasa  et al. evaluated the clinical and biologi-
cal significance of p21
WAF1/CIP1, p27
KIP1, c-myc, p53 and 
Ki67 expressions in ovarian cancer patients. Immunohisto-
chemical analysis was performed on 204 ovarian carcinomas 
of International Federation of Gynecology and Obstetrics 
(FIGO) stage IIB to IV treated with platinum-based chemo-
therapy. Endometrioid and clear cell carcinomas differed 
from other carcinomas by having a low incidence of p53 
accumulation, a high incidence of c-myc overexpression 
(70%) and a low median Ki67 labeling index (LI) (all with P 
<0.001). The authors have shown an independent predictive 
value of p21
WAF1/CIP1 LI in ovarian carcinoma patients. The 
prognostic value of p21
WAF1/CIP1 and p21
WAF1/CIP1 plus p27
KIP1 
LI was determined by p53(-) status. A high frequency of c-
myc overexpression in endometrioid and clear cell carcino-
mas may suggest its role in the development of these tumor 
types [14]. High-level p16 expression was observed in se-
rous and endometrioid phenotypes, with a positive relation to 
high levels of both cell proliferation and p53 abnormalities. 
None of 131 cases analyzed by Saegusa et al. showed a 
methylation status of the p16 gene promoter [15]. Two dif-
ferent studies also revealed no evidence of methylation and 
low levels of mutations [16] [17]. However there are some 
data supporting p16 promoter hypermethylation as a mecha-
nism underlying the downregulation of the gene. Milde-
Langosch  et al. found hypermethylation in 12/19 negative 
cases, most of them mucinous and endometrioid carcinomas 
[18]. Alterations in p15  were observed in serous, endo-
metrioid and clear cell but not in mucinous carcinomas, sug-
gesting that inactivation of p15 may be the histological type-
specific event in ovarian tumorigenesis [19]. 
CLEAR CELL CARCINOMAS 
  Ovarian clear cell carcinoma revealed significantly in-
creased cyclin E associated with an increase in p21
WAF1/CIP1, 
compared to the other histological subtypes [20]. 
  Clear cell carcinoma revealed such trends as low expres-
sion of both p53 and cyclin A and significantly increased 
expression of both p21
WAF1/CIP1 and cyclin E compared with 
the other histologic subtypes. In all ovarian carcinomas, a 
very strong positive correlation between p53 positive stain-
ing and cyclin A positive staining and a weak positive corre-
lation between p21
WAF1/CIP1 positive staining and cyclin E 
positive staining were recognized at the level of expression 
of cell cycle regulatory molecules. Clinical stage was the 
only independent predictive factor for the survival of the 
patients. Among ovarian adenocarcinomas, clear cell carci-
noma exhibits a unique pattern of expression of cell cycle 
regulatory molecules, though in this study the survival did 
not correlate with histologic subtype, only with clinical stage 
[20]. 
  Cyclin E expression is significantly higher in clear cell 
carcinoma than in serous carcinoma and is significantly re-
lated with p53 positivity [21]. 
 Akahane  et al. demonstrated that some genetic altera-
tions, which induce p53 mutations in endometriosis, may 
affect malignant transformation of endometriosis into ovar-
ian clear cell carcinoma [22].  
UNDIFFERENTIATED CARCINOMAS 
  The molecular changes in undifferentiated carcinomas of 
the ovary remain largely unknown [23]. 
  In a recent study carried out by Rosen et al. overexpres-
sion of cyclin E was found in 63.2% of the 405 primary 
ovarian carcinomas analyzed and was associated with clear 
cell, undifferentiated, and serous carcinoma (P < or = .001), 
high-grade tumors (P < or = .001), late-stage disease (P = 
.002), age older than 60 years at the time of diagnosis (P = 
.04), and suboptimal cytoreduction (P = .001). A high per-
centage of cyclin E-expressing cells was associated with a 
poor outcome in univariate and in multivariate analyses. In 
addition, cyclin E levels also reduced survival in the late-
stage disease group and in patients who underwent subopti-
mal debulking. Cyclin E was identified as an independent 
prognostic factor in patients with ovarian carcinoma. The 
accumulation of cyclin E protein may be a late event in tu-
morigenesis and may contribute to disease progression in 
these patients [24] 
CONCLUSIONS 
  The identified molecular changes in epithelial ovarian 
cancers can facilitate the rational development of new diag-
nostic modalities and tailored therapies for these malignan-
cies. Most of the G1-S regulators play an important role in 
ovarian cancer due to the fact that they control the G1-S tran-
sition, a crucial step in cell cycle control. Cyclin E is a key 
regulator of the G1-S transition. Abnormalities in cyclin E 
expression have been related to survival in a variety of can-
cers. Cyclin E plays an important role in ovarian carcino-
genesis of clear cell, undifferentiated, and serous carcinomas 
and its overexpression may be an indicator of a poor progno-
sis. Cyclin E expression is significantly higher in clear cell 
carcinoma than in serous carcinoma and is significantly re-
lated with p53 positivity. Overexpression of cyclin E was 
also found to be associated with undifferentiated carcinomas 
of the ovary. The actual mutation of p53 is the most common 
molecular alteration occurring in both early-stage and inva-
sive ovarian carcinomas, especially in those of serous histol-
ogy, and confers resistance to chemotherapy and lead to 
shortened overall survival. Epithelial ovarian tumors show-
ing p53 alterations are significantly less sensitive to chemo-
therapy and more aggressive than those with functional p53 
and overall survival is shortened in patients with p53 muta-
tions [25, 26]. In serous carcinomas the combination of 
p21
WAF1/CIP1 loss and p53 overexpression was independently 
predictive of a shorter progression-free interval. Coexpres-
sion of p21
WAF1/CIP1 and MDM2 characterizes serous border-
line tumors of the ovary and their implants, which suggests 
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tumors and may be related to tumor progression. Low 
p21
WAF1/CIP1 expression combined with p16 overexpression is 
considered to be the indicator for a poor prognosis in serous 
ovarian cancer. 
  Mucinous and endometrioid carcinomas are largely char-
acterized by p16 downregulation and the gene promoter hy-
permethylation. Lack of p16 is associated with p53 wt (wild 
type) and is typical of mucinous and endometrioid tumors. 
Little is known about the role of p15 in ovarian carcinomas. 
No mutations have been detected. Its inactivation may be the 
histological type-specific event in ovarian tumorigenesis. 
Alterations in p15 gene occur in serous, endometrioid and 
clear cell carcinomas but not in mucinous carcinomas. There 
are also a number of studies reporting no correlation between 
the expression of cell cycle genes and the different histo-
types of ovarian carcinoma. 
  In fact, cyclin D1 and c-Myc which are key participants 
in the cell-cycle pathway are frequently overexpressed in 
epithelial ovarian carcinomas, but they are not correlated 
with a particular histologic subtype [27] and p27
KIP1 subcel-
lular location in the cytoplasm
 was independently associated 
with poorer survival among women
 with ovarian carcinoma, 
particularly for those with late-stage
 disease and regardless 
of tumor histotype [28].  
  The described abnormalities of cell cycle regulators in 
ovarian carcinomas (Fig. 1) suggest that most of the cell cy-
cle regulatory genes play a crucial role in ovarian carcinoma 
tumorigenesis and/or development. The main goal in cancer 
therapy remains an early diagnosis of the disease, and some 
of the cell cycle genes described could be useful markers for 
achieving this goal, and therefore more targeted therapies. 
GLOSSARY 
BRCA1 and BRCA2 
  Tumor suppressor genes. 
Cyclins 
  Family of genes involved in the progression of cells 
through the cell cycle. 
Cyclin E 
  Gene that regulates cell cycle. Cyclin E is one of the key 
regulators of the G1/S transition in the cell cycle. Cyclin E 
binds to G1 phase Cdk2, which is required for the transition 
from G1 to S phase. 
Cyclin D Family 
  Family of three closely related genes termed cyclin D1, 
D2 and D3 that are expressed in an overlapping redundant 
fashion in all proliferating cell types and collectively control 
the progression of cells through the cell cycle. 
Cyclin D1 
  Gene that belongs to Cyclin D family of genes which 
function as the regulatory subunits of cyclin/cyclin depend-
ent kinase (Cdk) holoenzymes that regulate entry into and 
progression through the cell cycle. 
CDK 2 (Cyclin-Dependent Kinase 2) 
  Gene that regulates cell cycle. CDK2 is a member of a 
large family of protein kinases that initiates the principal 
transitions of the eukaryotic cell cycle. 
CDK4 (Cyclin-Dependent Kinase 4) 
  Gene that regulates cell cycle. The complexes formed by 
CDK4 and the D-type cyclins are involved in the control of 
cell proliferation during the G1 phase. CDK4 is inhibited by 
p16
INK4a. 
CDK 6 (Cyclin-Dependent Kinase 6) 
  Gene that regulates cell cycle. The activity of this kinase 
first appears in mid-G1 phase, which is controlled by the 
regulatory subunits including D-type cyclins and members of 
INK4 family of CDK inhibitors. This kinase, as well as 
CDK4, has been shown to phosphorylate, and thus regulate 
the activity of tumor suppressor protein pRb. 
Cyclin A 
  Gene that regulates cell cycle. Cyclin A binds to S phase 
Cdk2 and is required for the cell to progress through the S 
phase of cell cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic model of cell cycle regulator genes involved in carcinogenesis of the different histotypes in epithelial ovar-
ian cancer. The question mark in the undifferentiated tumor section underlines that the role of cell cycle genes in this histotype 
of ovarian cancer is largely unknown. Cell Cycle Genes in Ovarian Carcinoma  The Open Clinical Cancer Journal, 2008, Volume 2    11 
Cyclin B 
  Gene that regulates cell cycle. Cyclin B is a mitotic cy-
clin. The amount of cyclin B (which binds to Cdk1) and the 
activity of the cyclin B-Cdk complex rise through the cell 
cycle until mitosis, where they fall abruptly due to degrada-
tion. 
c-myc 
  Oncogene overexpressed in a wide range of human can-
cers. 
INK4 Family 
  Family of cyclin-dependent kinase inhibitors.  
KI-67 
  Gene associated with cell proliferation. 
MDM2 
  Target gene of the transcription factor tumor gene p53; 
its overexpression inhibits p53 gene. 
p53 
  Tumor suppressor gene. 
p27
KIP1 
  Tumor suppressor gene. p27
KIP1 belongs to the family of 
cell cycle regulators called cyclin-dependent kinase inhibi-
tors (CDKI), which bind to "cyclin-CDK" complexes and 
cause cell cycle arrest in the G
1 phase. 
p21
WAF1/CIP1 
  Tumor suppressor gene. This gene encodes a potent cy-
clin-dependent kinase inhibitor. The encoded protein binds 
to and inhibits the activity of cyclin-CDK2 or -CDK4 com-
plexes, and thus functions as a regulator of cell cycle pro-
gression at G1. The expression of this gene is tightly con-
trolled by the tumor suppressor protein p53, through which 
this protein mediates the p53-dependent cell cycle G1 phase 
arrest in response to a variety of stress stimuli. 
Rb (Retinoblastoma Gene) 
  Tumor suppressor gene. Rb prevents the cell from repli-
cating damaged DNA by preventing its progression through 
the cell cycle into its S (synthesis phase) or progressing 
through G1 (first gap phase). 
pRb (Retinoblastoma Protein) Pathway 
  The pRb pathway plays a key role in controlling the G1/S 
transition in cell cycle progression. 
p16
INK4a 
  Gene that belongs to INK4 gene family. p16 is a tumor 
suppressor gene. 
p15
INK4b 
  Gene that belongs to INK4 gene family. p15INK4b is a 
specific inhibitor of cdk4/cdk6 and is periodically expressed 
during cell cycle. 
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